[go: up one dir, main page]

WO2011106650A3 - Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease - Google Patents

Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease Download PDF

Info

Publication number
WO2011106650A3
WO2011106650A3 PCT/US2011/026251 US2011026251W WO2011106650A3 WO 2011106650 A3 WO2011106650 A3 WO 2011106650A3 US 2011026251 W US2011026251 W US 2011026251W WO 2011106650 A3 WO2011106650 A3 WO 2011106650A3
Authority
WO
WIPO (PCT)
Prior art keywords
mdm2
mdm4
antagonists
novel
proliferative disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/026251
Other languages
French (fr)
Other versions
WO2011106650A2 (en
Inventor
Alexander Doemling
Tad Holak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of WO2011106650A2 publication Critical patent/WO2011106650A2/en
Publication of WO2011106650A3 publication Critical patent/WO2011106650A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

High-resolution structural information delineates key interactions between MDM2 or MDM4 and heterocyclic compounds that bind to these proteins. These compounds are potent agonists of the p53-MDM2/p53-MDM4 complex.
PCT/US2011/026251 2010-02-27 2011-02-25 Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease Ceased WO2011106650A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30892510P 2010-02-27 2010-02-27
US61/308,925 2010-02-27

Publications (2)

Publication Number Publication Date
WO2011106650A2 WO2011106650A2 (en) 2011-09-01
WO2011106650A3 true WO2011106650A3 (en) 2012-01-19

Family

ID=44507586

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/026251 Ceased WO2011106650A2 (en) 2010-02-27 2011-02-25 Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease

Country Status (1)

Country Link
WO (1) WO2011106650A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008210434C8 (en) 2007-01-31 2014-03-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
KR20160061439A (en) 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Stitched polypeptides
PH12012500870A1 (en) 2009-11-12 2012-11-26 Univ Michigan Regents Spiro-oxindole mdm2 antagonists
DK2603600T3 (en) 2010-08-13 2019-03-04 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
PE20140408A1 (en) 2010-11-12 2014-04-10 Univ Michigan SPIRO-OXINDOL DERIVATIVES AS ANTAGONISTS OF MDM2
EP2707372B1 (en) 2011-05-11 2016-12-21 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
RU2639523C2 (en) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Peptidomimetic macrocycles and their application
RU2642299C2 (en) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. p53 PEPTIDOMIMETIC MACROCYCLES
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CN103497164B (en) * 2013-09-23 2015-12-23 西安近代化学研究所 A kind of anthracene derivant and preparation method thereof
JP2018503595A (en) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Peptidomimetic macrocycle and its preparation
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US9809539B2 (en) * 2015-03-03 2017-11-07 Shuttle Pharmaceuticals, Llc Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
HK1249104A1 (en) 2015-03-13 2018-10-26 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as hdac8 inhibitors
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
EP3371173A4 (en) * 2015-11-02 2019-06-19 Carmel-Haifa University Economic Corporation Ltd. APOPTOSIS-RELATED PROTEIN MIMETIC COMPOUNDS IN THE TGF-BETA SIGNALING PATHWAY (ARTS), COMPOSITIONS, METHODS AND USES THEREOF FOR INDUCING THE DIFFERENTIATION AND / OR APOPTOSIS OF PRECANCEROUS AND MALIGNANT CELLS, AND RECOVERING THEM THEIR PHENOTYPE OF THE NORMAL TYPE
US10000458B2 (en) * 2016-03-31 2018-06-19 Sumitomo Chemical Company, Limited Production method of 1, 2, 4-triazole compound
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3565549B1 (en) 2017-01-09 2022-03-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
IT201700041723A1 (en) 2017-04-14 2018-10-14 Italfarmaco Spa New HDAC6 selective inhibitors
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293319A1 (en) * 2005-06-24 2006-12-28 Kim-Chun Luk Oxindole derivatives
WO2008119741A2 (en) * 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
WO2008130614A2 (en) * 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US20090143364A1 (en) * 2004-05-18 2009-06-04 Nader Fotouhi Chiral cis-imidazolines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143364A1 (en) * 2004-05-18 2009-06-04 Nader Fotouhi Chiral cis-imidazolines
US20060293319A1 (en) * 2005-06-24 2006-12-28 Kim-Chun Luk Oxindole derivatives
WO2008119741A2 (en) * 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
WO2008130614A2 (en) * 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists

Also Published As

Publication number Publication date
WO2011106650A2 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
WO2011106650A3 (en) Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
LTC2307454I2 (en) Stable and soluble antibodies that inhibit VEGF
LT2766395T (en) ANTIBODY POLYPEPTIDES AS CD40L ANTAGONISTS
PL2621526T3 (en) DRUGS AND ANTIBODIES (ADC) CON conjugates WHICH BIND PROTEIN 191P4D12
PT2547679E (en) 2,3-DIHYDRO-1H-INDENE-1-IL-2,7-DIAZASPIRO DERIVATIVES [3.6] NONANO AND ITS USE AS ANTAGONISTS OR INVERSE AGONISTS OF GRELINA RECEPTOR
MX2022008904A (en) SYNTHESIS OF GAMMA-FUSIONED CARBOLINES WITH SUBSTITUTED HETEROCYCLE.
MX386437B (en) ANTI-FAP ANTIBODIES AND METHODS OF USE.
MX2013005847A (en) Multispecific antigen binding proteins targeting hgf.
PL2593452T3 (en) Heterocyclic compounds that are agonists of the IP receptor
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
EP2606061B8 (en) Binding proteins for hepcidin
CR20130271A (en) ESPIRO-OXINDOL MDM2 ANTAGONISTS
EP2338127A4 (en) CRYPTOGRAPHIC ACCUMULATORS FOR AUTHENTICATED HASHING TABLES
EP2424877A4 (en) SUPERCHARGED PROTEINS FOR CELL PENETRATION
WO2011047087A3 (en) Protein detection via nanoreporters
IL221205A (en) Antibody drug conjugates (adc) that bind to 161p2f10b proteins, compositions comprising the same and uses thereof
BRPI1006134A2 (en) antibody or functional antibody fragment, pharmaceutical composition, use of an antibody or functional fragment thereof, polynucleotide, vector, and transformed host cell.
MA34025B1 (en) POLYPEPTIDES BINDING TO BETA-A
EA201171494A1 (en) MIMETIC PROTEINS SMAC
EP2858151A4 (en) BINDER FOR BATTERY ELECTRODE AND ELECTRODE AND BATTERY USING THE SAME
WO2015048484A3 (en) Binding moieties for biofilm remediation
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
EA201390254A1 (en) MODIFIED RELAXIN POLYPEPTIDES AND THEIR APPLICATION
BR112013008255A2 (en) isolated antibody or functional fragment thereof, use of an isolated antibody or functional fragment thereof, pharmaceutical composition, polynucleotide, vector, transformed cell, and method for producing antibody
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11748150

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11748150

Country of ref document: EP

Kind code of ref document: A2